At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
gemcitabine +1 moredrug
Likely dose
gemcitabine 1250 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Gemcitabine-Paclitaxel 3-Weekly Schedule as First-Line Treatment in Metastatic Breast Cancer After Anthracycline Failure
In Brief
A Phase 2 clinical trial evaluating gemcitabine and paclitaxel for Metastatic Breast Cancer. Completed, enrolled 60 participants across 3 sites.
Detailed Summary
The purpose of this study is to determine the response rate to a gemcitabine-paclitaxel combination administered on a 3-weekly schedule in Chinese patients with unresectable, locally recurrent breast cancer or metastatic breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2006
First PostedApr 2006
Primary CompletionApr 2008
TodayJul 2026
First PostedApr 20, 2006
Enrollment StartApr 1, 2006
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 20.2 years ago
Interventions
gemcitabinedrug
1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days until disease progression
paclitaxeldrug
175 mg/m2, intravenous (IV), every 21 days until disease progression